Abstract
Transplantation-associated thrombotic microangiopathy (TMA) is one of the main complications after hematopoietic stem cell transplantation (HSCT). At the time of onset of gut TMA, a patient developed a high titer of an inhibitor of the non—immunoglobulin G type to ADAMTS13, which physiologically hydrolyzes von Willebrand factor to control spontaneous intravascular thrombus formation.The patient developed symptoms of myositis, a disorder that has occasionally been reported to manifest after HSCT and to resemble some idiopathic autoimmune diseases. However, a muscle biopsy specimen presented pathologic findings of TMA, including microvascular platelet thrombus formation, without inflammatory lymphocyte infiltration. ADAMTS13 activities returned to normal after steroid treatment, and the improvement of TMA symptoms followed. This patient appears to represent a rare case of post-HSCT TMA associated with the development of an ADAMTS13 inhibitor.
Similar content being viewed by others
References
Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994;14:495–504.
Busca A, Uderzo C. BMT: bone marrow transplant associated thrombotic microangiopathy. Hematology. 2000;5:53–67.
Selby DM, Rudzki JR, Bayever ES, Chandra RS. Vasculopathy of small muscular arteries in pediatric patients after bone marrow transplantation. Hum Pathol. 1999;30:734–740.
Hirabayashi N. Thrombotic microangiopathy (TMA), 1: TMA in the target organs of graft-versus-host disease [in Japanese]. Rinsho Ketsueki. 2000;41:491–495.
Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant. 2004;33:1143–1150.
Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584.
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594.
Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program). 2004:407–423.
van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798–3802.
Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol. 2002;75:25–34.
Kato S, Matsumoto M, Matsuyama T, Hiura H, Fujimura Y. Monoclonal antibodies to a VWF-A2 decapeptide with the C-terminal residue Tyr1605, generated by ADAMTS13 cleavage, develop a highly sensitive ELISA for its activity and characterize Upshaw-Schulman syndrome [abstract]. Blood. 2005;106:742a. Abstract 2643.
Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood. 2004;103:607–612.
Nelson KR, McQuillen MP. Neurologic complications of graft-versus-host disease. Neurol Clin. 1988;6:389–403.
Collins PW, Gutteridge CN, O’Driscoll A, et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant. 1992;10:499–506.
Pham PT, Danovitch GM, Wilkinson AH, et al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002;74:1077–1080.
Nakazawa Y, Hashikura Y, Urata K, et al. von Willebrand factor—cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Liver Transpl. 2003;9:1328–1333.
Kierdorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med. 1993;118:987–988.
Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004;103:1305–1310.
Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115:2752–2761.
Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42:34–39.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Adachi, T., Matsushita, T., Ichihashi, R. et al. High Titer of ADAMTS13 Inhibitor Associated with Thrombotic Microangiopathy of the Gut and Skeletal Muscle after Allogeneic Hematopoietic Stem Cell Transplantation. Int J Hematol 83, 415–419 (2006). https://doi.org/10.1532/IJH97.05157
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.05157